

DOPAMINERGIC MODULATION OF  
MELANIN-CONCENTRATING HORMONE  
EXPRESSING NEURONS

ROBERT BARRY TRASK









**DOPAMINERGIC MODULATION OF MELANIN-CONCENTRATING  
HORMONE EXPRESSING NEURONS**

**By**

**Robert Barry Trask**

**A thesis submitted to the  
School of Graduate Studies  
in partial fulfillment of the  
requirements for the degree of  
Master of Science in Medicine**

**Faculty of Medicine**

**Memorial University**

**March 2009**

**St. John's**

**Newfoundland and Labrador**

## **Abstract**

Melanin-concentrating hormone (MCH) is a neuropeptide that acts centrally as an anabolic signal, while also mediating behaviours such as reward, activity level, and anxiety. MCH expressing neurons are limited in their expression being isolated to the lateral hypothalamus (LH) and nearby zona incerta (ZI). Despite this limited area of expression the neurons project widely throughout the brain. The neurotransmitter/neuromodulator dopamine (DA), which is best known for its role in reward and locomotion, is released within the LH area. DA action within the LH area is known to influence MCH related behaviours: for example, an injection of DA into the LH will decrease food intake. Since MCH promotes food intake and DA has anorexic properties in the LH it is hypothesized that DA inhibits the activity of the MCH expressing neurons. However, DA's mechanism of action on MCH neurons is not known. This study was carried out to determine the cellular mechanisms by which DA influences MCH expressing neurons. To determine this MCH neuronal activity was monitored using whole cell patch-clamp recordings from LH/ZI containing rat brain slices. MCH neurons were identified and distinguished from nearby orexin neurons by their electrophysiological characteristics and post-hoc immunohistochemistry. All drugs were bath applied. In order to monitor DA's presynaptic influence  $\gamma$ -aminobutyric acid (GABA) release was recorded through pharmacologically isolated miniature inhibitory postsynaptic currents (mIPSCs). Results showed that DA inhibits the activity of MCH expressing neurons through hyperpolarization and a reduction in action potential firing.



Furthermore, DA induced a dose dependent outward current. This current was the result of G protein-activated inwardly rectifying K<sup>+</sup> (GIRK) channel activation. Surprisingly, initiation of the GIRK current was not dependent on DA receptor activation but rather on the highly expressed adrenergic  $\alpha_{2A}$  receptor. Norepinephrine (NE) also produced a reversible, dose dependent outward current in MCH neurons when acting on the adrenergic receptors. The DA and NE induced outward currents were of similar magnitudes, indicating both have similar efficacies when acting on MCH neurons. Monitoring mIPSCs revealed that DA had no consistent effect on their frequency or amplitude, indicating that DA does not influence synaptic GABA transmission. Overall this study demonstrates that DA has a direct postsynaptic inhibitory influence on MCH neurons. This inhibition is accomplished through activation of adrenergic receptors and the initiation of a GIRK current. Furthermore, this study reveals a cross talk between dopaminergic and adrenergic signalling at the cellular level within the LH area.

## **Acknowledgements**

I would like to thank Dr. Michiru Hirasawa, my supervisor, for providing mentorship and guidance during my graduate education.

I would also like to thank my supervisory committee members, Dr. Dale Corbett and Dr. Xihua Chen, as well as the rest of the faculty, students and staff within Biomedical Sciences.

Finally, I would like to thank my parents, Barry and Debbie Trask, along with my brother David for all their support during my education. Without them this would not have been possible.



## Table of Contents

Abstract	ii
Acknowledgements	iv
Table of Contents	v
List of Figures	viii
List of Abbreviations	iv
 <b>CHAPTER 1</b>	 <b>1</b>
 <b>Introduction</b>	 <b>1</b>
 1.1 Overview	 1
1.2 History and Structure	2
1.3 Expression in the CNS	3
1.4 Neurochemical Properties	3
1.5 Physiological Roles of MCH	4
1.5.1 Food intake	4
1.5.2 Reward	5
1.5.3 Other Behaviours	5
1.6 Electrophysiological properties	6
1.7 Neurotransmitter interactions	7
1.8 DA expression in CNS and association with MCH	8
1.9 DA influences MCH related behaviours	9
1.10 Summary and Hypothesis	10

<b>CHAPTER 2</b>	<b>11</b>
<b>Materials and Methods</b>	<b>11</b>
2.1 Animal Model	11
2.2 Slice Preparation	11
2.3 Setup	12
2.4 Cell Identification	12
2.5 Electrophysiological Recordings	13
2.5.1 Current-clamp mode	13
2.5.2 Voltage-clamp mode	13
2.6 Immunohistochemistry	14
2.7 Data Analysis	14
2.8 Chemical Compounds	15
 <b>CHAPTER 3</b>	 <b>16</b>
<b>Results</b>	<b>16</b>
3.1 Identification of MCH expressing neurons	16
3.2 Effect of DA on MCH neurons (current-clamp)	17
3.3 Postsynaptic effect of DA on MCH neurons (voltage-clamp)	17
3.4 DA activates GIRK channels	18
3.5 Receptors mediating DA's response	19
3.6 Comparison of DA vs NE effect on MCH neurons	20
3.7 Synaptic effect of DA on MCH neurons (voltage-clamp)	21

<b>CHAPTER 4</b>	<b>22</b>
<b>Discussion</b>	<b>22</b>
4.1 Distinguishing MCH and Orexin neurons	22
4.2 DA hyperpolarizes MCH neurons	23
4.3 DA induces a GIRK mediated current	23
4.4 DA induced outward current is not DA receptor mediated	25
4.5 DA induced outward current is $\alpha_{2A}$ -adrenoceptor mediated	26
4.6 DA mimics NE's effect on MCH neurons	28
4.7 DA's hyperpolarization of MCH neurons is not synaptically mediated	29
4.8 Conclusion	30
<b>REFERENCES</b>	<b>32</b>

## List of Figures

<u>Figure 1</u>	
Identification of MCH and orexin neurons	42
<u>Figure 2</u>	
DA hyperpolarizes and diminishes firing of MCH neurons	43
<u>Figure 3</u>	
DA induces a concentration dependent outward current in MCH neurons	44
<u>Figure 4</u>	
DA-induced outward current due to activation of GIRK channels in MCH neurons	45
<u>Figure 5</u>	
DA-induced outward current is initiated through the activation of $\alpha_2$ -adrenoceptors and not DA receptors in MCH neurons	46
<u>Figure 6</u>	
DA-induced outward current is due to the activation of $\alpha_{2A}$ -adrenoceptors in MCH neurons	47
<u>Figure 7</u>	
DA and NE-induced outward currents are similar in MCH neurons	48
<u>Figure 8</u>	
DA has no consistent effect on mIPSC frequency or amplitude	49



## **List of Abbreviations**

AC – Adenylyl cyclase

ACSF – Artificial cerebrospinal fluid

ACTH - Adrenocorticotrophic hormone

AMCA - Aminomethylcoumarin acetate

ATP – Adenosine triphosphate

BRL44408 - 2-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-2,3-dihydro-1-methyl-1H-  
isoindole maleate

CART - Cocaine-and amphetamine regulated transcript

CNS – Central nervous system

Cy2 – Cyanine dye that fluoresces green

Cy3 - Cyanine dye that fluoresces red

DA – Dopamine

D-AP5 - D-2-amino-5-phosphonopentanoate

D1-like – D1-like dopamine receptors

D2-like – D2-like dopamine receptors

DMSO - Dimethyl sulfoxide

DNQX - 6,7-Dinitroquinoxaline-2,3-dione

GABA -  $\gamma$ -aminobutyric acid

GAD- Glutamic Acid Decarboxylase

GIRK - G Protein-activated Inwardly Rectifying  $K^+$

ICV – Intracerebroventricular

IgG – Immunoglobulin G

$I_h$  – H current

IR-DIC - Infrared differential inference contrast

HPA - Hypothalamic-pituitary adrenal

LH - Lateral hypothalamus

MCH - Melanin-concentrating hormone

MCHR1 – MCH receptor 1

MCHR2 - MCH receptor 2

mEPSC - miniature excitatory postsynaptic current

mIPSC - miniature inhibitory postsynaptic current

NAc - Nucleus accumbens

NE – Norepinephrine

NK3 - Neuokinin receptor

NPY – Neuropeptide Y

Ob-R - Leptin receptor

OXR1 – Orexin receptor 1

OXR2 – Orexin receptor 2

PBS - Phosphate buffered saline

PTX - Pertussis toxin

RT-PCR - Reverse transcriptase polymerase chain reaction

SCH23390 - R-(+)-7-Chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride

SD - Sprague Dawley

SKF81297 - 6-Chloro-2,3,4,5-tetrahydro-1-phenyl-1H-3-benzazepine hydrobromide

SN – Substantia nigra

TTX - Tetrodotoxin

VGLUT1 - Vesicular glutamate transporter 1

VTA – Ventral tegmental area

ZI - Zona incerta



## **CHAPTER 1**

### **Introduction**

#### **1.1 Overview**

Melanin-concentrating hormone (MCH) is a cyclic neuropeptide that centrally participates in the regulation of numerous behaviours including feeding, reward, stress, and locomotor activity. Through animal studies MCH has been shown to function as an anabolic signal in energy homeostasis. It communicates hedonic aspects of feeding, activates the stress axis, and decreases an animal's activity level. Due to these functions an unbalanced regulation of the MCH system may be associated with the development and maintenance of obesity. In order to fully understand the MCH system and to develop pharmaceutical therapies for diseases like obesity, it is crucial that the cellular mechanisms regulating MCH neuronal activity are described.

The neurotransmitter/neuromodulator dopamine (DA) may be one of the critical regulators of the MCH system. This is because similar to MCH, DA influences behaviours such as feeding, response to reward, and locomotion. Also, DA projections are known to intersect MCH's neuronal origins and terminal fields. Thus, some of the physiological functions of DA may be mediated by MCH. However, despite the possibility that DA directly influences MCH neuronal activity, its mechanism of action is not known. My goal is to determine DA's effect on MCH neuronal activity and the mechanisms regulating it.



## 1.2 History and structure

The MCH neuropeptide was first identified due to its skin lightening role in Teleosts (Baker & Ball, 1975; Westerfield *et al.*, 1980). The primary sequence was first identified in 1983 from isolated chum salmon pituitaries as a 17-amino-acid peptide (Kawauchi *et al.*, 1983), with a dicysteine bridge at positions 5 and 14 forming a ring structure. Subsequent to its discovery in fish, MCH was identified in the mammalian hypothalamus (Vaughan *et al.*, 1989). The mammalian form of MCH is a cyclic 19-amino-acid peptide that is highly homologous to the chum salmon MCH. Identification of the MCH receptor was made collectively (Bachner *et al.*, 1999; Chambers *et al.*, 1999; Lembo *et al.*, 1999; Saito *et al.*, 1999; Shimomura *et al.*, 1999) and denoted MCHR1. MCH binds to MCHR1 with nanomolar affinity and the receptor can couple to  $G_i$ ,  $G_o$ , or  $G_q$  proteins to activate multiple intracellular signaling pathways (Hawes *et al.*, 2000). Subsequent to the identification of MCHR1, a second MCH receptor has been identified in humans (An *et al.*, 2001; Hawes *et al.*, 2000; Rodriguez *et al.*, 2001) and denoted MCHR2. MCHR2 was found to be a pseudogene in rodent species, but is functional in dogs, ferrets, rhesus monkeys, and humans (Tan *et al.*, 2002). However, due to the lack of available animal models the functional importance of MCHR2 remains largely unknown. The overall homology of MCHR2 to MCHR1 is relatively low for a family of receptors that bind to the same ligand with about a 38% amino-acid similarity (Sailer *et al.*, 2001). This indicates that the two receptors are more divergent in evolution than other GPCR families.

### **1.3 Expression in the CNS**

Central nervous system (CNS) expression of the MCH neuropeptide is limited to the lateral hypothalamus (LH) and the zona incerta (ZI). These neurons project widely throughout the brain and are distributed throughout the CNS in patterns that generally conform to known projection fields of the LH and ZI (Bittencourt et al., 1992). These include the prefrontal cortex, dorsal and ventral striatum, piriform cortex, olfactory tubercle, hippocampal formation, nucleus accumbens (NAc), amygdala, and various nuclei in the hindbrain, such as the nucleus tractus solitarius and the parabrachial nucleus. MCHR1 and MCHR2 expression coincides with MCH neuronal projection fields (An et al., 2001; Hervieu et al., 2000; Hill et al., 2001; Saito et al., 2000).

### **1.4 Neurochemical properties**

Through quantitative immunocytochemical identification and analysis with laser microdissection and semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR) a multi-transcriptional profiling of the intrinsic characteristics of MCH neurons in the rat LH was established (Harthoorn et al., 2005). MCH neurons were shown to express the neuropeptides MCH, cocaine- and amphetamine regulated transcript (CART), and dynorphin. Furthermore, MCH neurons expressed the glutamate marker vesicular glutamate transporter (VGLUT)-1 and the  $\gamma$ -aminobutyric acid (GABA) markers glutamic acid decarboxylase (GAD)-65 and GAD-67, thus indicating the presence and possible dispersal of both excitatory and inhibitory transmitters.



## 1.5 Physiological Roles of MCH

### 1.5.1 Food intake

MCH was first thought to be involved in food intake because it was expressed within the LH. The LH has long been thought of as the “hunger center” of the brain due to classic lesion/stimulation studies (for review see Schwartz et al., 2000). This notion was supported when it was observed that MCH mRNA was increased in leptin deficient, obese, *ob/ob* mice (Zhang et al., 1994). An increase in MCH RNA was also observed after fasting in both lean and *ob/ob* mice (Qu et al., 1996). Furthermore, intracerebroventricular (ICV) injection of MCH tripled food intake in rodents, an effect that lasted for up to six hours (Qu et al., 1996; Rossi et al., 1997). MCH’s role as an orexigenic neuropeptide was confirmed through gene knockout and over expression studies. It was discovered that when the MCH gene was knocked out (MCH<sup>-/-</sup>) mice were hypophagic and lean compared to their wild type littermates (Shimada et al., 1998). Also, their resting energy expenditure was elevated, which accounted in part for their leanness. Furthermore, when the MCH gene was over expressed in mice fed a high fat diet they were 12.6% heavier than the wild-type controls fed the same diet. Also the obese mice were found to be hyperphagic (Ludwig et al., 2001). During in-vitro brain slice experiments the MCH neuropeptide was shown to stimulate orexigenic neurons of the arcuate nucleus, while inhibiting anorexigenic neurons of the ventromedial hypothalamus (Davidowa et al., 2002), thus providing cellular correlates of its role as an orexigenic neuropeptide.

### **1.5.2 Reward**

It has been suggested that signaling between the LH and NAc plays an important role in communicating the hedonic, or rewarding, aspects of feeding (Saper et al., 2002). Evidence for this view include the fact that the MCHR1 is robustly expressed in the ventral and dorsal striatum, the terminal fields of midbrain dopaminergic neurons which are involved in mediating reward (Saito et al., 2001). Furthermore, injection of MCH directly into the medial NAc shell increases food intake (Georgescu et al., 2005). Research to date suggests that MCH signaling in the NAc is a starvation induced signal that influences the reward pathway to increase the drive to feed (Georgescu *et al.*, 2005; Kelley & Berridge, 2002; Saper *et al.*, 2002).

### **1.5.3 Other Behaviours**

MCH is believed to play a physiological role to suppress excessive activity. In support of this, MCH injected ICV in rats has been shown to inhibit the increase in locomotor activity, grooming, and rearing induced by neuropeptide E-I (peptide produced from the same prohormone as MCH) injection (Sanchez et al., 1997). Also, genetic inactivation of MCHR1 in mice results in increased spontaneous locomotor activity (Marsh et al., 2002).

MCH neuronal activation has also been described to promote sleep following sustained waking (Modirrousta et al., 2005). If MCH does in fact decrease activity level and promote sleep, then direct inhibition of MCH neurons by arousal systems would be a means to prevent the opposing effects of MCH. This is in fact the case with



neurotransmitters that can initiate arousal such as norepinephrine (NE), serotonin, muscarine, and cholinergic agonists, inhibit the activity of MCH neurons (van den Pol et al., 2004; Wollmann et al., 2005) .

MCH is also believed to play a role in the physiological regulation of anxiety and stress. Several lines of evidence show that MCH activates stress responses and induces depressive and anxiety-like behaviours, while the blockade of MCHR1 results in antidepressant and anxiolytic effects in various rodent models. MCH has been shown to activate the hypothalamic-pituitary adrenal (HPA) axis (Kennedy et al., 2003), with ICV injection of MCH increasing circulating adrenocorticotrophic hormone (ACTH) up to 10 min post injection. Furthermore, rats given the MCHR1 antagonist, SNAP7941, showed a decrease in anxiety and depression during a forced swim test (Borowsky et al., 2002). Antidepressant effects have also been observed after MCHR1 antagonist injection into the medial shell of the NAc (Georgescu et al., 2005). This suggests that MCHR1 may play a substantial role in mediating anxiety and depressive-like behaviours and may form the basis for future pharmaceutical approaches to the treatment of these diseases.

## **1.6 Electrophysiological properties**

Knowledge of the electrophysiological properties of MCH neurons is crucial for the identification of the cells in in-vitro brain slice preparation while also providing a foundation for the understanding of all MCH governed behaviours. MCH neurons are intermixed with another population of peptidergic neurons, i.e. orexin neurons, which have similar morphological characteristics. Because they cannot be distinguished by their

appearance with differential interference contrast optics, with which we identify neurons suitable for recordings in brain slices, differences in their electrophysiological properties are used. Orexin neurons are also known as an important regulator of food intake (for review see Sakurai T., 2006) and thus a significant research topic, however, this thesis will only focus on MCH neurons. MCH neuronal electrophysiological properties do not correspond to the spontaneously active orexin neurons. In a previous study we found in in-vitro acute brain slice preparation that MCH neurons were relatively hyperpolarized with an average resting membrane potential of -58.8mV, while the orexin neurons were comparatively depolarized at an average of -48.6mV (Alberto et al., 2006). Other electrical properties of MCH neurons provide insight into their lack of spontaneous activity. They do not have an  $I_h$  (sag during a hyperpolarizing current pulse) or rebound depolarization (after a hyperpolarizing current pulse) as the orexin neurons do. However, they do show strong spike rate adaptation during depolarization current pulses (Alberto et al., 2006; Eggermann et al., 2003; Gao et al., 2003). Overall compared to spontaneously active orexin neurons the electrophysiological properties of MCH neurons appear to maintain quiescence when synaptic activity is absent.

### **1.7 Neurotransmitter interactions**

MCH neurons receive a variety of inputs from different neurotransmitter systems that regulate their activity. For example, glutamate, ATP and orexin A and orexin B depolarize and increase the activity of MCH neurons (van den Pol et al., 2004). However, neuropeptide Y (NPY), a potent orexigenic hypothalamic neuropeptide, inhibits MCH



neurons (van den Pol et al., 2004). This may be a negative feedback mechanism due to the fact that MCH stimulates NPY neurons (Davidowa et al., 2002). Other neurotransmitters, including norepinephrine, serotonin, muscarine or cholinergic agonists, inhibit MCH neurons (van den Pol et al., 2004; Wollmann et al., 2005).

Numerous cell surface receptors have been identified on MCH neurons including GABA receptors, glutamate receptors, OXR1 and OXR2 orexin receptors, leptin receptors, neuokinin receptors, chemokine receptors, muscarinic receptors, serotonergic receptors, and  $\alpha_2$ -adrenoceptors (Gao et al., 2003; Griffond et al., 1997; Guyon et al., 2005; Hakansson et al., 1999; van den Pol et al., 2004). DA receptors have also been identified in the LH area (Bubser et al., 2005; Fetissov et al., 2002). Overall MCH neurons receive numerous excitatory and inhibitory afferents signals that are processed by the corresponding cell surface receptor. The cellular mechanisms that are initiated by the activated receptors determine the cellular response and consequently the functional behaviour.

## **1.8 DA expression in CNS and association with MCH neurons**

The neurotransmitter/neuromodulator DA is largely known for its involvement in modulating the reward and motor systems. DA is expressed within neurons located in several regions of the mammalian CNS including the substantia nigra (SN), ventral tegmental area (VTA), and the retrorubal area. Dopaminergic neurons are also located in the hypothalamus within the arcuate nucleus and ZI. Some of these areas form the origin for the three main dopaminergic pathways, the nigrostriatal, the mesolimbocortical, and

the tuberoinfundibular pathway (for review see Bjorklund & Dunnett, 2007). With respect to MCH neurons the majority of the DA fibers within the LH area arise from the VTA (Leibowitz & Brown, 1980; Yoshida *et al.*, 2006), and, DA has been shown to be released within the LH (Fetissov *et al.*, 2000). Furthermore, DA expressing neurons exist within the ZI (Bjorklund *et al.*, 1975). Therefore, DA is positioned to directly interact with MCH neurons and possibly influence their activity.

DA receptors are expressed widely throughout the brain with high expression levels in the striatum, NAc and the prefrontal cortex (Bouthenet *et al.*, 1991; Dearry *et al.*, 1990). There are five subtypes of DA receptors classified into 2 groups based on sequence homology. DA receptors 1 and 5 are known as D1-like, while DA receptors 2, 3, and 4 are the D2-like. All DA receptors are G protein dependent with D1-like coupled to  $G_s$  and activating adenylyl cyclase (AC), while D2-like receptors are coupled mainly to  $G_{i/o}$  and inhibit AC (for review see Missale *et al.*, 1998). Activation of either receptor can modulate cellular activity through numerous cellular mechanisms such as the modulation of cellular calcium and potassium channels, and the  $Na^+-K^+-ATPase$  pump. Also, the D2-like receptors can inhibit the  $Na^+/H^+$  exchanger and activate arachidonic release (for review see Missale *et al.*, 1998).

### **1.9 DA influences MCH related behaviours**

DA has largely been described based on its involvement with the reward and motor systems, however DA has been shown to modulate MCH related behaviours. For example DA has been shown to play an important role in regards to energy homeostasis.



Transgenic rodent models with altered DA receptors or reuptake have a strong influence on weight gain and food reinforcement. It was shown that when DA transporters are eliminated, therefore increasing DA levels in the extracellular space, there is a reduction in energy intake (Epstein & LeDdy, 2006). Furthermore, DA has been shown to have an inhibitory impact on food intake when acting within the LH. DA receptor activation inhibits feeding (Sederholm et al., 2002), while the D2-like receptor antagonist sulpiride blocks the anorexic effect of DA in the LH (Parada et al., 1988). Also, different energy states (fasting/obesity) modulate DA receptor expression and DA release within the LH (Fetissov et al., 2002). Therefore, DA's anorexic properties within the LH may be mediated at least partially through the modulation of MCH neuronal activity.

#### **1.10 Summary and Hypothesis**

It is evident that MCH expressing neurons play substantial roles in numerous physiological functions including stimulating food intake and maintaining energy homeostasis. In contrast, behavioural studies have shown DA to have a negative effect on food intake and energy homeostasis when acting within the LH area where MCH neurons exist. Therefore, I hypothesized that DA inhibits the activity of MCH neurons. Using the in-vitro patch-clamp technique I have examined the effect of DA on the electrophysiological activity of MCH neurons and the cellular mechanisms involved.

## CHAPTER 2

### Materials and Methods

#### 2.1 Animal Model

Male Sprague Dawley (SD) rats (60-90g) were used in this study and were obtained from Memorial University Vivarium (VT1000 Leica Microsystems). The rats were housed with food and water available *ad-libitum* and with a room temperature of  $21^{\circ}\text{C} \pm 1^{\circ}\text{C}$ . Also controlled were light/dark cycle (12/12hrs), humidity, and air circulation. All experiments were conducted in accordance with the guidelines set by the Canadian Council on Animal Care and were approved by the Memorial University of Newfoundland Internal Animal Care Committee. Only the number of animals necessary to produce reliable results was used.

#### 2.2 Slice Preparation

The rats were deeply anesthetized with halothane and decapitated. The brain was removed and with the aid of a vibratome 250 $\mu\text{m}$  coronal hypothalamic brain slices were generated at  $0-2^{\circ}\text{C}$  in buffer solution composed of the following (in mM): 87 NaCl, 2.5 KCl, 1.25  $\text{NaH}_2\text{PO}_4$ , 7  $\text{MgCl}_2$ , 0.5  $\text{CaCl}_2$ , 25  $\text{NaHCO}_3$ , 25 glucose, 30 sucrose, 3 pyruvic acid, 1 ascorbic acid. Slices were then incubated at  $33-34^{\circ}\text{C}$  for 30-45 min and then held at room temperature in artificial cerebrospinal fluid (ACSF) composed of (in mM) 126 NaCl, 2.5 KCl, 1.2  $\text{NaH}_2\text{PO}_4$ , 1.2  $\text{MgCl}_2$ , 2  $\text{CaCl}_2$ , 25  $\text{NaHCO}_3$ , 10 glucose, 1 ascorbic



acid. Both solutions were continuously bubbled with a combination of O<sub>2</sub> (95%) and CO<sub>2</sub> (5%).

### **2.3 Setup**

A hemisected brain slice was placed in the recording chamber of the microscope setup and continuously perfused with 33–34°C ACSF at 1.5–2.0ml/min. Whole-cell patch-clamp recording was performed using a Multiclamp 700B amplifier and pClamp 9.2 software (Molecular Devices, Sunnyvale, CA). The pipette tip resistance of the recording electrode was 3–7 M $\Omega$  when filled with the internal solution composed of (in mM): 128 K-gluconate, 8 KCl, 2 MgCl<sub>2</sub>, 0.2 EGTA, 10 HEPES, 4 Na<sub>2</sub>-ATP, 0.3 Na-GTP, pH 7.3. A high chloride concentration internal solution composed of (in mM): 132 KCl, 2 MgCl<sub>2</sub>, 0.2 EGTA, 10 HEPES, 4 Na<sub>2</sub>-ATP, 0.3 Na-GTP, pH 7.3, was used to aid in miniature inhibitory postsynaptic current (mIPSC) detection. Biocytin (1–1.5 mg/ml) was also included in the internal solution to label recorded neurons.

### **2.4 Cell Identification**

To aid in the localization of MCH neurons, an infrared differential interference contrast microscope (IR-DIC) (DMLFSA; Leica Microsystems) was used for visual detection. Neurons adjacently lateral and dorsal to the fornix with a diameter of 10–20 $\mu$ m were selected. Once the cells were patched they were injected with a series of hyperpolarizing and depolarizing 300ms step pulses in current clamp mode in order to characterize the electrophysiological properties of the cell.

## **2.5 Electrophysiological Recordings**

### **2.5.1 Current-clamp mode**

Current-clamp mode was used to monitor membrane potential and action potential firing. The current was clamped at 0 pA so the cells could remain at rest. Because MCH neurons are silent at rest in our preparation, 200 pA depolarization current pulses 300msec in duration were given every 20-60 sec to monitor action potential firing. Membrane currents were filtered at 10 kHz, sampled at 5 kHz and stored for off-line analysis.

### **2.5.2 Voltage-clamp mode**

Voltage-clamp mode was used to monitor the direction of current flow. Cells were held at a membrane potential of  $-70$  mV in the presence of tetrodotoxin (TTX) ( $1\mu\text{M}$ ) to block  $\text{Na}^+$ -dependent action potentials. During mIPSC experiments, DNQX ( $10\mu\text{M}$ ) and D-AP5 ( $10\mu\text{M}$ ) were used to block glutamatergic transmission in addition to TTX. Membrane currents were filtered at 1 kHz, digitized at 5 kHz and stored for off-line analysis. A 20 mV hyperpolarizing pulse lasting for 100 ms was applied every 20–60 s throughout each experiment, and the steady state current and decay rate of the capacitance transient were monitored as measures of input resistance and series/access resistance, respectively. Cells that showed significant change in these parameters were excluded from additional analysis.



## **2.6 Immunohistochemistry**

After the electrophysiological recordings were completed a representative number of cells were saved for immunohistochemical analysis. When the electrophysiological recording was completed the brain slice was immediately placed in 4% paraformaldehyde in 0.1 M PBS overnight at 4°C, then washed and stored in PBS before the addition of primary antibodies. To aid in distinguishing between MCH neurons and the orexin neurons that occupy similar areas slices were incubated with anti-orexin A goat polyclonal IgG (1:3000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA) and anti-MCH rabbit polyclonal IgG (1:2000 dilution; Phoenix Pharmaceuticals, Belmont, CA) for 3 days at 4°C. Since all orexin neurons contain both the orexin A and the orexin B neuropeptides only anti-orexin A was used. Slices were then washed and treated for 3 h with a combination of Cy3-conjugated donkey anti-goat antibody, Cy2-conjugated donkey anti-rabbit antibody, and streptavidin-conjugated aminomethylcoumarin acetate (AMCA), all at 1:500 dilution at room temperature. Antibodies were diluted with PBS with 0.03% Triton X. Slices were then washed, mounted, and examined under a fluorescence microscope for detection of orexin A (Cy3), MCH (Cy2) immunoreactivity, and biocytin (AMCA).

## **2.7 Data Analysis**

Current and voltage-clamp data was detected and analyzed using Clampfit 9.2 software (Axon Instruments). mIPSC's were further detected and analyzed using minianalysis 6.0 software (Synaptosoft, Decatur, GA). The data are expressed as mean  $\pm$

SE. Statistical comparisons were performed by using appropriate tests (i.e., Kolmogorov Smirnov test for testing individual cells, and unpaired or paired Student's *t* tests, or ANOVA for group comparison as appropriate). Dose response curves and EC<sub>50</sub> calculations were performed using GraphPad Prism software. GraphPad Prism and minianalysis 6.0 were used for statistical analysis. A value of  $p < 0.05$  was considered to be significant.

## **2.8 Chemical Compounds**

All drugs were bath perfused at final concentrations as indicated, by diluting aliquots of 1000X stock in the ACSF immediately before use. DA and NE stock solutions included the anti-oxidant ascorbic acid (1 mM) and were light protected during the recordings to minimize oxidation. Dimethyl sulfoxide (DMSO) was used to solubilize appropriate compounds in stock solutions and the final concentration of DMSO was 0.1%.

SKF 81297, quinpirole, SCH 23390, sulpiride, tertiapin-Q, yohimbine, BRL 44408, and imiloxan were purchased from Tocris Bioscience (Ellisville, MO), dopamine, norepinephrine, biocytin, DNQX, and D-AP5 from Sigma Aldrich (St. Louis, MO), and tetrodotoxin from Alomone Labs (Jerusalem, Israel).

## CHAPTER 3

### Results

#### 3.1 Identification of MCH expressing neurons

MCH expressing neurons were targeted based on their location within the LH and ZI and relatively large size. This was accomplished by using an IR-DIC microscope. However, orexin expressing neurons are also located in similar regions of the LH. Therefore, differentiating between the two types of cells was of extreme importance. Identification of MCH neurons was accomplished through immunohistochemical and electrophysiological means. Neurons were filled with biocytin via patch pipette, and their neurochemical phenotype was confirmed by an immunohistochemical method following recordings (Fig. 1B1, B2). Cells that were found to be MCH immunopositive ( $n = 17$ ) had distinct electrophysiological characteristics that were different from that displayed by orexin neurons (Fig. 1A1, A2). None of the MCH neurons displayed an  $I_h$  upon injection of a hyperpolarizing current and no rebound depolarization was revealed at the current offset. The average membrane potential was  $-57.95 \pm 1.54$  mV and the majority of them did not fire spontaneously (15 of 17, 88.2%). Also, fourteen of the seventeen neurons (82.4%) displayed strong spike rate adaptation (Fig. 1A1, A2). These results are consistent with other previous studies (Alberto et al., 2006; Eggermann et al., 2003; Gao et al., 2003).



A total of 65 MCH neurons from 40 rats were used in this study of which 17 cells were identified as MCH immunopositive and having typical electrophysiological characteristics as described above. Forty-eight cells were identified based on the electrophysiological properties only. Cells that did not meet the criteria of MCH neurons were excluded from the study.

### **3.2 Effect of DA on MCH neurons (current-clamp)**

100  $\mu$ M DA application caused a reversible hyperpolarization of MCH neurons (Fig. 2A,top). Since one of the identifying characteristics of MCH neurons is their lack of action potential firing at rest, a depolarizing current (200 pA, 300 msec) was given each minute to monitor DA's influence on action potential firing (Fig. 2A, bottom). As shown in Fig. 2B, 10 and 100  $\mu$ M DA application caused a decrease in action potential firing and increased the latency to the first induced action potential ( $n = 2$  respectively). In addition, DA application reduced input resistance during a  $-200$  pA, 300 msec current pulse (Fig. 2B3,  $n = 2$  respectively). However, DA application had no significant effect on spike threshold or width. Control values were  $-32.15 \pm 0.03$  mV and  $3.9 \pm 0.2$  msec respectively, while during DA application values were  $-35.31 \pm 0.26$  mV and  $3.4 \pm 0.2$  msec respectively ( $n = 4, p > 0.05$ ).

### **3.3 Postsynaptic effect of DA on MCH neurons (voltage-clamp)**

It is possible that DA inhibits MCH activity by either acting directly on the MCH neuron or by influencing synaptic inputs. To investigate the possible postsynaptic

mechanism voltage-clamp experiments were carried out in the presence of TTX (1  $\mu$ M). As shown in Fig. 3A, 100  $\mu$ M DA application caused a reversible outward current. This current is concentration dependent (Fig. 3B) at concentrations tested (0.1, 1, 3, 10, and 100  $\mu$ M). 0.1  $\mu$ M DA application did not induce a significant outward current ( $0.19 \pm 0.08$  pA,  $n = 3$ ,  $p > 0.05$ ). The lowest concentration to produce a significant current was 1  $\mu$ M ( $8.94 \pm 2.32$  pA,  $n = 4$ ,  $p < 0.05$ ). 3  $\mu$ M application induced a  $17.37 \pm 3.93$  pA outward current ( $n = 5$ ,  $p < 0.05$ ), while the current was also significant with the 10 and 100  $\mu$ M application ( $22.99 \pm 3.36$  pA,  $n = 5$ ,  $p < 0.05$  and  $20.52 \pm 2.38$  pA,  $n = 13$ ,  $p < 0.05$  respectively). Also, there was no statistical difference ( $p > 0.05$ ) for the currents produced from the 3, 10, or 100  $\mu$ M application. This indicates that a concentration of 3  $\mu$ M can initiate a maximal current with the DA's induced current having a steep concentration dependence. The  $EC_{50}$  of the DA induced outward current was 0.80  $\mu$ M.

### 3.4 DA activates GIRK channels

To determine the voltage dependence of the DA induced current the membrane potential was ramped before and during DA application and the resulting current response was measured (Fig. 4A1). In the two experiments carried out the reversal potential for the DA induced current was -91 mV, as shown in Fig. 4A2, and -89 mV (data not shown). The results are similar to the predicted potassium reversal potential of the solutions used in our experiments (-101 mV). The DA induced current also displayed an inward rectification similar to the G Protein-activated Inwardly Rectifying  $K^+$  (GIRK) current. To determine the contribution of GIRK channels to DA's effect, DA was applied



in the presence of the GIRK channel blocker tertiapin-Q (300nM). In the presence of Tertiapin-Q a 100 $\mu$ M DA application failed to initiate an outward current. This was statistically different from DA application alone [(Fig. 4B;  $2.91 \pm 0.85$ pA,  $n = 3$ ,  $p < 0.05$ ) (Fig. 4B2)]. This suggests that a GIRK mediated current is activated by DA application.

### 3.5 Receptors mediating DA's response

Next the receptor responsible for the outward current was investigated. There are two classes of DA receptors, namely D1-like (D1/D5) and D2-like receptors (D2/D3/D4). To examine the role of the receptors, the D1-like agonist SKF81297 (10 $\mu$ M) and D2-like agonist quinpirole (10  $\mu$ M) were simultaneously applied. To our surprise, these agonists failed to mimic the DA induced outward current [(Fig. 5A);  $-1.55 \pm 1.62$ ,  $n = 5$ ,  $p > 0.05$  (Fig. 5D)]. Furthermore, 100  $\mu$ M DA induced a significant outward current when applied in the presence of the D1-like antagonist SCH23390 (10  $\mu$ M) and the D2-like antagonist sulpiride (10  $\mu$ M) [(Fig. 5B);  $22.81 \pm 5.13$ ,  $n = 3$ ,  $p < 0.05$  (Fig. 4D)]. This suggests that DA receptors are not mediating the DA effect. Furthermore, as shown in Fig. 5B, the DA receptor antagonists did not affect the MCH neuron on their own. This suggests that the DA receptor antagonists are not participating in the outward current.

DA has the ability to activate adrenergic receptors (Brown & Caulfield, 1979), and activation of  $\alpha_2$ -adrenoceptors has been shown to hyperpolarize MCH neurons due to the activation of GIRK channels (van den Pol et al., 2004). Therefore, we hypothesize that DA activates  $\alpha_2$ -adrenoceptors on MCH neurons which in turn initiates the outward current. 100  $\mu$ M DA application in the presence of the  $\alpha_2$ -adrenoceptor antagonist



yohimbine (5  $\mu$ M) failed to induce an outward current [(Fig. 5C);  $-0.53 \pm 0.44$ ,  $n = 3$ ,  $p > 0.05$ , (Fig. 5D)]. This suggests dopaminergic activation of  $\alpha_2$ -adrenoceptors mediates the outward current.  $\alpha_2$ -adrenoceptors are classified into four subtypes, namely  $\alpha_{2A}$ ,  $\alpha_{2B}$ ,  $\alpha_{2C}$ , and  $\alpha_{2D}$ . Due to the high expression level of the  $\alpha_{2A}$  and  $\alpha_{2B}$  adrenoceptor subtypes within the LH (Wang et al., 2002; WinzerSerhan et al., 1997), these were investigated. Application of 10-100  $\mu$ M DA in the presence of  $\alpha_{2A}$  antagonist BRL44408 (3  $\mu$ M) failed to induce an outward current [(100  $\mu$ M, Fig. 6A); 10-100 $\mu$ M,  $2.38 \pm 2.11$ ,  $n = 5$ ,  $p > 0.05$ , (Fig. 6C)]. In contrast, application of 10-100  $\mu$ M DA in the presence of  $\alpha_{2B}$  antagonist Imiloxan (3 $\mu$ M) induced an outward current [(100 $\mu$ M, Fig. 6B); 10-100 $\mu$ M,  $16.77 \pm 7.81$ ,  $n = 2$ , (Fig. 6C)]. This suggests dopaminergic activation of the  $\alpha_{2A}$ -adrenoceptor subtype mediates the outward current.

### 3.6 Comparison of DA vs NE effects on MCH neurons

To determine whether DA was as effective as NE in modulating MCH neurons, the amplitude of DA and NE induced outward currents was compared. We found that NE application initiated an outward current in a dose dependent manner in MCH neurons (Fig. 7A and B). 0.1  $\mu$ M NE application did not induce a significant outward current ( $3.10 \pm 3.70$  pA,  $n = 4$ ,  $p > 0.05$ ). The lowest concentration of NE to produce a significant current was 1 $\mu$ M ( $11.46 \pm 4.49$  pA,  $n = 4$ ,  $p < 0.05$ ). 3 $\mu$ M application induced a  $18.98 \pm 1.84$  pA outward current ( $n = 4$ ,  $p < 0.05$ ), while the current was also significant with the 10 and 100 $\mu$ M application of NE ( $21.20 \pm 2.08$  pA,  $n = 3$ ,  $p < 0.05$  and  $24.99 \pm 2.38$  pA,  $n = 5$ ,  $p < 0.05$  respectively). The  $EC_{50}$  of the NE induced outward current was 1.23  $\mu$ M. As

shown in Fig. 7B the dose response curves of DA and NE are very similar with no significant differences between groups at concentrations tested ( $p>0.05$ ), indicating that their effects are of similar magnitudes. In a preliminary experiment an occlusion test was carried out in an attempt to confirm if DA and NE were acting on the same receptor. As shown in Fig. 7C addition of 100  $\mu$ M NE in the presence of 100  $\mu$ M DA does not induce any further outward current, supporting the idea that the same receptor is activated. However, the possibility remains that DA and NE are both activating GIRK channels but through the activation of different subtypes of adrenoceptors receptors.

### **3.7 Synaptic effect of DA on MCH neurons (voltage-clamp)**

To determine possible synaptic effects of DA on MCH neurons, mIPSCs were monitored in the presence of TTX (1  $\mu$ M). Application of 0.1, 1, 3, 10, and 100  $\mu$ M DA had no consistent effect on mIPSC frequency (Fig. 8A1), with the change in mIPSC frequency fluctuating independent of concentration. Some cells showed a significant increase in mIPSC frequency during DA application. For example 100  $\mu$ M DA application can increase the frequency of mIPSCs (Fig. 8A2,  $p<0.05$ ), while some cells were unchanged by 100  $\mu$ M DA application (Fig. 8A3,  $p>0.05$ ) However some cells had significantly decreased frequencies with DA application. For example, 100  $\mu$ M DA application decreased the frequency of mIPSCs in some cells (Fig. 8A4,  $p<0.05$ ). Also, no consistent effect on mIPSC amplitude was found with DA application (Fig. 8B). This suggests that DA induced hyperpolarization is not mediated by altered GABA release or GABA receptor activity



## CHAPTER 4

### Discussion

#### 4.1 Distinguishing MCH and Orexin neurons

Animal studies have shown that MCH functions as an anabolic signal in energy homeostasis, communicates hedonic aspects of feeding, activates the stress axis, and decreases an animal's activity level. In order for the MCH neuropeptide to be fully understood, the factors influencing its neuronal activity must be identified. However, the orexigenic neuropeptide orexin is also expressed in similar regions of the hypothalamus as the MCH neurons. Although MCH and orexin are both synthesized by neurons of the LH and maintain many overlapping projections, the two peptides are not co-localized in a single neuron (Broberger et al., 1998; Elias et al., 1998; Peyron et al., 1998). Therefore, distinguishing between the two neuronal types is of extreme importance. This study began with the confirmation of the electrophysiological characteristics associated with MCH and orexin expressing neurons as described in earlier studies (Eggermann et al., 2003; Gao et al., 2003). As shown in Fig. 1 our results confirmed the electrophysiological characteristics of both MCH and orexin neurons (Alberto et al. 2006). MCH neurons have a lower resting membrane potential compared to orexin neurons, do not fire spontaneously, show spike-rate adaptation, do not have an  $I_h$ , and do not display rebound depolarization. However, the orexin neuronal properties are different to that of MCH neurons because they have a higher resting membrane



potential, fire spontaneously, display no spike-rate adaptation, possess an  $I_h$ , and do display rebound depolarization. Therefore these distinguishing electrophysiological characteristics can be used as a reliable tool in the identification of the MCH and orexin neuronal groups.

#### **4.2 DA hyperpolarizes MCH neurons**

Mesolimbic dopaminergic projections are positioned ideally for direct interaction with MCH neurons (Duva *et al.*, 2005; Yoshida *et al.*, 2006; Leibowitz & Brown, 1980). Behavioural studies have also suggested that this interaction may directly modulate the activity of MCH neurons (Parada *et al.*, 1988; Yang *et al.*, 1997). Also, DA expressing neurons are located within the ZI, which in turn could directly influence MCH neurons (Cheung *et al.*, 1998). The present study demonstrates that DA causes a reversible hyperpolarization of MCH neurons. As observed in Fig. 2, DA hyperpolarizes the membrane potential of MCH neurons and reduces the action potential frequency. This reduction in action potential frequency coincides with the DA-induced increase in latency to the first action potential and to the decrease in input resistance. However, the spike threshold and width are not affected. Therefore, the DA induced hyperpolarization may prevent MCH related behaviours, such as food intake, from being initiated.

#### **4.3 DA induces a GIRK mediated current**

DA may hyperpolarize MCH neurons through direct postsynaptic mechanisms, presynaptic mechanisms, or a combination of the two. As observed in Fig 3, during the

voltage-clamp protocol, when the MCH neuron is isolated from its synaptic inputs through the use of TTX, DA induces a direct dose-dependent reversible outward current. This indicates that DA may induce its hyperpolarization at least in part through direct postsynaptic mechanisms. As shown in Fig. 4, the current-voltage relationship of the current has an inward rectification with a reversal potential approximately equal to the  $K^+$  equilibrium potential. Furthermore, the GIRK channel blocker tertiapin-Q abolished this current. Thus we concluded that DA activates a GIRK current in MCH neurons.

G protein-dependent stimulation of potassium channels has been described for numerous neurotransmitters in a variety of brain regions. Stimulation of GIRK currents in the CNS has been shown to be pertussis toxin (PTX) sensitive (Saugstad et al., 1996), and hence the involvement of a  $G_i$  protein. Major neurotransmitters within the CNS can activate a hyperpolarizing GIRK current, which include: GABA by  $GABA_B$  receptors in the hippocampus (Andrade et al., 1986; Otis et al., 1993), norepinephrine (NE) by  $\alpha_2$ -adrenoceptors in the locus coeruleus (Velimirovic et al., 1995), 5-HT in the locus coeruleus and cerebellum (Andrade et al., 1986; Andrade and Nicoll 1987), and by DA in the substantia nigra and in the pituitary lactotrophs (Kim et al., 1995). Activation of a GIRK current by NE has also been shown to induce the hyperpolarization of MCH neurons (van den Pol et al., 2004). Therefore, DA may be activating the GIRK current in MCH neurons through the activation of DA receptors, or through an indirect adrenergic mechanism.



#### **4.4 DA induced outward current is not DA receptor mediated**

It has been shown that addition of the D2-like receptor agonist quinpirole to brain slices hyperpolarizes substantia nigra neurons via the activation of a GIRK current during whole-cell patch clamp experiments (Kim et al., 1995). The GIRK current was blocked using the D2-like receptor antagonist sulpiride suggesting the direct activation of the D2-like receptor initiated the activation of GIRK channels, which led to the hyperpolarization. In contrast, as shown in Fig. 5, simultaneous application of D1 and D2 receptor agonists failed to mimic the DA induced outward current in MCH neurons. To ensure the D1 agonist was not counteracting a D2 initiated current, the D2-like agonist quinpirole was applied alone in some cells. Activation of D2 receptors alone also failed to initiate an outward current (data not shown). Furthermore addition of DA receptor antagonist failed to block the DA induced current. This suggests that DA is not initiating the GIRK current through a DA receptor based mechanism.

Evidence for DA receptor expression within the LH area is conflicting. One study on Zucker rats concluded that both D1 and D2 receptor mRNAs were present within the LH (Fetissov et al., 2002). PCR preparation for this study used a brain tissue chunk containing the LH. With this type of tissue preparation it is possible that surrounding areas outside of the LH were incorporated into the analysis. Therefore, a false positive may have been obtained with the DA receptors actually expressed outside the LH. A more recent study on SD rats, that used the spatially specific *in-situ* hybridization method, showed that D2 mRNA was scarce within the LH and D1 mRNA was not present (Bubser et al., 2005). However, these conflicting results may be due to the rat



strains used. The present study was undertaken with SD rats, therefore the low level on D2 expression and absence of D1 may explain why the D1-and D2-like agonists and antagonists had no effect on MCH neuronal activity. This suggests that the GIRK current is initiated through a DA receptor independent mechanism.

#### **4.5 DA induced outward current is $\alpha_{2A}$ -adrenoceptor mediated**

The possibility of insufficient DA receptor expression suggests that DA may be acting within the LH through the activation of adrenergic receptors. Evidence supporting this includes the fact that  $\alpha_2$ -adrenoceptors are heavily expressed within the LH (Wang et al., 2002; WinzerSerhan et al., 1997). As previously shown by van den Pol *et al.*, (2004), NE has the ability to induce a hyperpolarizing GIRK current through the activation of the PTX sensitive  $\alpha_2$ -adrenoceptors in MCH neurons. DA and NE are both catecholaminergic neurotransmitters and DA is known to show cross reactivity to adrenergic receptors (Brown & Caulfield, 1979). Therefore, the possibility exists that DA is initiating the outward current through the activation of the adrenergic system. As observed in Fig. 5, blocking the  $\alpha_2$ -adrenoceptors prevents the initiation of the DA induced outward current. The  $\alpha_{2A}$  and  $\alpha_{2B}$  adrenoceptor subtypes are the most predominantly expressed  $\alpha_2$ -adrenoceptors in the LH area (Wang et al., 2002; WinzerSerhan et al., 1997). Further investigation into the receptor subtype revealed that the  $\alpha_{2A}$  receptor activation was initiating the outward current.

NE itself shares similarities with DA's influence on MCH related behaviours, such as inhibiting food intake (Wellman et al. 1993). On the other hand earlier studies

demonstrated that NE release within the hypothalamus was increased during feeding (Hoebel et al., 1989), and that NE dose-dependently increased food intake by chemical stimulation of the LH (Shiraishi, 1991). Wellman et al. (1993) demonstrated that NE effect on food intake was dependent on which adrenergic receptor was activated within the paraventricular nucleus of the hypothalamus. When  $\alpha_2$ - receptors are activated it increased food intake, however  $\alpha_1$  – activation decreased food intake. Therefore, a possible explanation of NE's opposing influence on ingestive behaviour may be due to the type of adrenergic receptor that is activated and its location in the hypothalamus. All adrenergic receptors are G-protein coupled with the  $\alpha_1$ -receptors coupled to  $G_q$ , while the  $\alpha_2$ - are coupled to the  $G_i$ , and the adrenergic  $\beta$ -receptors are  $G_s$  coupled, for review see Michelotti et al., (2000). Therefore, the possibility exists that activation of the inhibitory  $G_i$  protein within the orexigenic MCH neuronal population by the  $\alpha_2$ -adrenoceptors would inhibit their activity and thus decrease food intake. On the other hand activation of the stimulatory  $G_s$  protein and even the  $G_q$  proteins within the LH by the  $\alpha_1$ - and  $\beta$ -receptors may stimulate the MCH and/or orexin neurons and thus increase food intake. Evidence supporting this hypothesis is the fact that  $\alpha_1$ -,  $\alpha_2$ , and  $\beta$ -adrenoceptors are all expressed within the LH (Wang et al., 2002; WinzerSerhan et al., 1997; Day et al., 1997; Castillo-Melendez et al., 2000), while NE action within the hypothalamus produces conflicting effects on food intake.



#### **4.6 DA mimics NE's effect on MCH neurons**

Activation of adrenoceptors within the CNS has been shown to reduce food intake (Wellman et al., 1993). This evidence taken with the fact that NE activation of  $\alpha_2$ -adrenoceptors directly hyperpolarizes MCH neurons, suggests that NE may interact with MCH neurons to inhibit food intake. Also MCH is known to activate the stress responses and induces depressive- and anxiety-like behaviours, while the blockade of MCH receptors results in antidepressant and anxiolytic effects in various models (Kennedy et al., 2003; Borowsky et al., 2002). With this in mind, preventing the release of the MCH neuropeptide into the CNS through adrenergic inhibition of MCH neurons may result in altered HPA axis function. This is indeed the fact with altered HPA axis activation resulting from an increase in central adrenergic signaling (Morilak et al., 2005). Therefore adrenergic activation of  $\alpha_2$ -adrenoceptors on MCH neurons may result in the direct regulation of food intake and the stress response. Since NE and DA both inhibit MCH neuronal activity through the activation of  $\alpha_2$ -adrenoceptors, which may result in altered MCH related behaviours, the questions arise whether DA's effects on MCH neurons through the adrenergic receptor are of a similar magnitude to the effect of NE itself, and secondly whether the same  $\alpha_2$ -adrenoceptors are being activated.

As observed in Fig. 7, NE produced a dose dependent reversible outward current that is in agreement with previous research (van den Pol et al., 2004). The amplitude of the outward current induced by NE and DA is similar at the same concentrations. Even though our data suggest that DA shows cross reactivity with adrenergic receptors this



observation was surprising due to the fact that DA has an affinity for  $\alpha_2$ -adrenoceptors 10-28-fold lower than that of NE (Cornil and Ball, 2008). Cornil and Ball (2008) demonstrated this lower affinity in whole rat brain homogenates, therefore the possibility remains that anatomical specificity may determine the magnitude of DA and NE cross reactivity and that DA may have a higher affinity for  $\alpha_2$ -adrenoceptors within the LH in order to compensate for the low DA receptor expression.

To examine whether the outward current was initiated through the same receptors, an occlusion experiment was conducted. As shown in Fig. 7, the addition of NE in the presence of DA did not alter the outward current suggesting that in fact the same  $\alpha_2$ -adrenoceptors mediated the outward current. Therefore it can be concluded that DA is regulating the same adrenergic system in MCH neurons as NE itself, and with similar efficacies.

#### **4.7 DA's hyperpolarization of MCH neurons is not synaptically mediated.**

Since MCH neuronal activity is modulated by GABA and glutamate transmission (van den Pol et al., 2004), the possibility remains that dopaminergic modulation of glutamate and/or GABA synapses may contribute to its inhibitory effect on MCH neuronal activity. To aid in determining the synaptic influence of a neurotransmitter, mIPSC's and miniature excitatory postsynaptic currents (mEPSC's) can be utilized as an electrophysiological tool. Miniature events inform the researcher on the spontaneous release of transmitters that are action potential independent. Therefore, how a compound influences the release machinery of the presynaptic terminals and the conductivity of the

postsynaptic channels can be studied. Previous research within our laboratory focused on DA's influence on mEPSC's and mIPSC's in orexin neurons within the LH. These studies found that DA decreases glutamate release and increases GABA release onto orexin neurons (Alberto *et al.*, 2006; Trask *et al.*, 2005). In contrast, we have found in the present study that DA has no consistent effect on mIPSC frequency or amplitude in MCH neurons (Fig. 8), regardless of the concentration used. DA influenced the frequency and amplitude of mIPSC's by increasing them in some cells, decreasing in some, and having no effect in others. Previous research within the laboratory also revealed that DA had no effect on mEPSC frequency or amplitude in MCH neurons. Taken together, our results suggest that synaptic modulation of glutamate and GABA receptors is not a mechanism by which DA inhibits MCH neurons.

#### **4.8 Conclusion**

From this study it can be concluded that DA hyperpolarizes MCH neurons through the activation of a GIRK current by the direct postsynaptic activation of  $\alpha_{2A}$ -adrenoceptors. In general the inhibition of MCH neurons by DA may help explain DA's influence on MCH related behaviours, such as DA's anorexigenic properties when acting within the LH. More specifically this is the first study to demonstrate a cross talk between DA and adrenergic signaling at the cellular level within the LH area. If the DA receptor expression is low in the LH, as Bubser *et al.*, (2005) suggested, then this cross talk may provide an explanation on how the DA input to the LH can influence MCH related behaviours. This study suggests that the abundant postsynaptic expression of  $\alpha_{2A}$ -

adrenoceptors within the LH may serve as the mediator necessary for DA effects. This mechanism may also help explain why DA and NE have similar effects on MCH related behaviours.



## REFERENCE LIST

- Alberto, C. O., Trask, R. B., Quinlan, M. E., & Hirasawa, M. (2006). Bidirectional dopaminergic modulation of excitatory synaptic transmission in orexin neurons. *J Neurosci.* **26**, 10043-10050.
- An, S. Z., Cutler, G., Zhao, J. J., Huang, S. G., Tian, H., Li, W. B., Liang, L. M., Rich, M., Bakleh, A., Du, J., Chen, J. L., & Dai, K. (2001). Identification and characterization of a melanin-concentrating hormone receptor. *PNAS* **98**, 7576-7581.
- Andrade, R., Malenka, R., & Nicoll, R. (1986). A G protein couples serotonin and GABA<sub>B</sub> receptors to the same channels in hippocampus. *Science.* **234**, 1261-1265.
- Bachner, D., Kreienkamp, H. J., Weise, C., Buck, F., & Richter, D. (1999). Identification of melanin concentrating hormone (MCH) as the natural ligand for the orphan somatostatin-like receptor 1 (SLC-1). *Febs Letters* **457**, 522-524.
- Baker, B. I. & Ball, J. N. (1975). Evidence for A Dual Pituitary Control of Teleost Melanophores. *Gen Comp Endocr.* **25**, 147-152.
- Bittencourt, J. C., Presse, F., Arias, C., Peto, C., Vaughan, J., Nahon, J. L., Vale, W., & Sawchenko, P. E. (1992). The Melanin-Concentrating Hormone System of the Rat-Brain - An Immunization and Hybridization Histochemical Characterization. *J Comp Neurol.* **319**, 218-245.
- Bjorklund, A. & Dunnett, S. B. (2007). Dopamine neuron systems in the brain: an update. *Trends in Neurosci.* **30**, 194-202.
- Bjorklund, A., Lindvall, O., & Nobin, A. (1975). Evidence of An Incerto-Hypothalamic Dopamine Neuron System in Rat. *Brain Res.* **89**, 29-42.
- Borowsky, B., Durkin, M. M., Ogozalek, K., Marzabadi, M. R., DeLeon, J., Lagu, B., Heurich, R., Lichtblau, H., Shaposhnik, Z., Daniewska, I., Blackburn, T. P., Branchek, T. A., Gerald, C., Vaysse, P. J., & Forray, C. (2002). Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. *Nature Medicine* **8**, 825-830.

Bouthenet, M. L., Souil, E., Martres, M. P., Sokoloff, P., Giros, B., & Schwartz, J. C. (1991). Localization of Dopamine-D3 Receptor Messenger-Rna in the Rat-Brain Using Insitu Hybridization Histochemistry - Comparison with Dopamine-D2 Receptor Messenger-Rna. *Brain Res.* **564**, 203-219.

Broberger, C., de Lecea, L., Sutcliffe, J. G., & Hokfelt, T. (1998). Hypocretin/orexin- and melanin-concentrating hormone-expressing cells form distinct populations in the rodent lateral hypothalamus: Relationship to the neuropeptide Y and Agouti gene-related protein systems. *J Comp Neurol.* **402**, 460-474.

Brown, D. A. & Caulfield, M. P. (1979). Hyperpolarizing Alpha-2 Adrenoceptors in Rat Sympathetic-Ganglia. *Brit J Pharmacol.* **65**, 435-445.

Bubser, M., Fadel, J. R., Jackson, L. L., Meador-Woodruff, J. H., Jing, D., & Deutch, A. Y. (2005). Dopaminergic regulation of orexin neurons. *Eur.J Neurosci.* **21**, 2993-3001.

Castillo-Melendez, M., Mckinley, M., Summers, R. Intracerebroventricular administration of the beta(3)-adrenoceptor agonist CL 316243 causes Fos immunoreactivity in discrete regions of rat hypothalamus. (2000). *Neurosci Lett.* **290**, 161-164.

Chambers, J., Ames, R. S., Bergsma, D., Muir, A., Fitzgerald, L. R., Hervieu, G., Dytko, G. M., Foley, J. J., Martin, J., Liu, W. S., Park, J., Ellis, C., Ganguly, S., Konchar, S., Cluderay, J., Leslie, R., Wilson, S., & Sarau, H. M. (1999). Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1. *Nature* **400**, 261-265.

Cheung, S., Ballew, J. R., Moore, K. E., & Lookingland, K. J. (1998). Contribution of dopamine neurons in the medial zona incerta to the innervation of the central nucleus of the amygdala, horizontal diagonal band of Broca and hypothalamic paraventricular nucleus. *Brain Res.* **808**, 174-181.

Cornil, C.A., Ball, G.F. (2008). Interplay among Catecholamine System: Dopamine Binds to  $\alpha_2$ -Adrenergic Receptors in Birds and Mammals. *J Comp Neurol.* **511**, 610-627.

Dascal, N. (1997). Signalling via the G protein-activated K<sup>+</sup> channels. *Cell Signal.* **9**, 551-573.



Davidowa, H., Li, Y. Z., & Plagemann, A. (2002). Hypothalamic ventromedial and arcuate neurons of normal and postnatally overnourished rats differ in their responses to melanin-concentrating hormone. *Regul Peptides* **108**, 103-111.

Day, H., Campeau, S., Watson, S., Akil, H. (1997). Distribution of  $\alpha_{1a}$ -,  $\alpha_{1b}$ - and  $\alpha_{1d}$ -adrenergic receptor mRNA in the rat brain and spinal cord. *J Chem Neuroanat.* **13**, 115-139.

Dearry, A., Gingrich, J. A., Falardeau, P., Freneau, R. T., Bates, M. D., & Caron, M. G. (1990). Molecular-Cloning and Expression of the Gene for A Human D1 Dopamine Receptor. *Nature* **347**, 72-76.

Duva, M. A., Tomkins, E. M., Moranda, L. M., Kaplan, R., Sukhaseum, A., & Stanley, B. G. (2005). Origins of lateral hypothalamic afferents associated with N-methyl-D-aspartic acid-elicited eating studied using reverse microdialysis of NMDA and Fluorogold. *Neurosci Res.* **52**, 95-106.

Eggermann, E., Bayer, L., Serafin, M., Saint-Mleux, B., Bernheim, L., Machard, D., Jones, B. E., & Muhlethaler, M. (2003). The wake-promoting hypocretin-orexin neurons are in an intrinsic state of membrane depolarization. *J Neurosci.* **23**, 1557-1562.

Elias, C. F., Saper, C. B., Maratos-Flier, E., Tritos, N. A., Lee, C., Kelly, J., Tatro, J. B., Hoffman, G. E., Ollmann, M. M., Barsh, G. S., Sakurai, T., Yanagisawa, M., & Elmquist, J. K. (1998). Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. *J Comp Neurol.* **402**, 442-459.

Epstein, L. H. & LeDdy, J. J. (2006). Food reinforcement. *Appetite* **46**, 22-25.

Fetissov, S. O., Meguid, M. M., Chen, C., & Miyata, G. (2000). Synchronized release of dopamine and serotonin in the medial and lateral hypothalamus of rats. *Neurosci.* **101**, 657-663.

Fetissov, S. O., Meguid, M. M., Sato, T., & Zhang, L. H. (2002). Expression of dopaminergic receptors in the hypothalamus of lean and obese Zucker rats and food intake. *Am J Physiol Reg I.* **283**, R905-R910.



Gao, X. B., Ghosh, P. K., & van den Pol, A. N. (2003). Neurons synthesizing melanin-concentrating hormone identified by selective reporter gene expression after transfection in vitro: transmitter responses. *J Neurophysiol.* **90**, 3978-3985.

Georgescu, D., Sears, R. M., Hommel, J. D., Barrot, M., Bolanos, C. A., Marsh, D. J., Bednarek, M. A., Bibb, J. A., Maratos-Flier, E., Nestler, E. J., & DiLeone, R. J. (2005). The hypothalamic neuropeptide melanin-concentrating hormone acts in the nucleus Accumbens to modulate feeding Behavior and forced-swim performance. *Journal of Neurosci.* **25**, 2933-2940.

Griffond, B., Ciofi, P., Bayer, L., Jacquemard, C., & Fellmann, D. (1997). Immunocytochemical detection of the neurokinin B receptor (NK3) on melanin-concentrating hormone (MCH) neurons in rat brain. *J Chem Neuroanat.* **12**, 183-189.

Guyon, A., Banisadr, G., Rovere, C., Cervantes, A., Kitabgi, P., Melik-Parsadaniantz, S., & Nahon, J. L. (2005). Complex effects of stromal cell-derived factor-1 alpha on melanin-concentrating hormone neuron excitability. *Eur J Neurosci.* **21**, 701-710.

Hakansson, M., de Lecea, L., Sutcliffe, J. G., Yanagisawa, M., & Meister, B. (1999). Leptin receptor- and STAT3-immunoreactivities in hypocretin/orexin neurones of the lateral hypothalamus. *J Neuroendocrinol.* **11**, 653-663.

Harthoorn, L. F., Sane, A., Nethé, M., & Van Heerikhuize, J. J. (2005). Multi-transcriptional profiling of melanin-concentrating hormone and orexin-containing neurons. *Cell Mol Neurobiol.* **25**, 1209-1223.

Hawes, B. E., Kil, E., Green, B., O'Neill, K., Fried, S., & Graziano, M. P. (2000). The melanin-concentrating hormone receptor couples to multiple G proteins to activate diverse intracellular signaling pathways. *Endocrinology* **141**, 4524-4532.

Hervieu, G. J., Cluderay, J. E., Harrison, D., Meakin, J., Maycox, P., Nasir, S., & Leslie, R. A. (2000). The distribution of the mRNA and protein products of the melanin-concentrating hormone (MCH) receptor gene, *slc-1*, in the central nervous system of the rat. *Eur J Neurosci.* **12**, 1194-1216.

Hill, J., Duckworth, M., Murdock, P., Rennie, G., Sabido-David, C., Ames, R. S., Szekeres, P., Wilson, S., Bergsma, D. J., Gloger, I. S., Levy, D. S., Chambers, J. K., &

Muir, A. I. (2001). Molecular cloning and functional characterization of MCH2, a novel human MCH receptor. *J Bio Chem.* **276**, 20125-20129.

Hoebel, BG., Hernandez, L., Schwartz, DH., Mark, GP., Hunter, GA. (1989). Microdialysis studies of brain norepinephrine, serotonin, and dopamine release during ingestive behavior. Theoretical and clinical implications. *Ann N Y Acad Sci.* **575**, 171-193.

Kawauchi, H., Kawazoe, I., Tsubokawa, M., Kishida, M., & Baker, B. I. (1983). Characterization of Melanin-Concentrating Hormone in Chum Salmon Pituitaries. *Nature* **305**, 321-323.

Kelley, A. E. & Berridge, K. C. (2002). The neuroscience of natural rewards: Relevance to addictive drugs. *J Neurosci.* **22**, 3306-3311.

Kennedy, A. R., Todd, J. F., Dhillon, W. S., Seal, L. J., Ghatei, M. A., O'Toole, C. P., Jones, M., Witty, D., Winborne, K., Riley, G., Hervieu, G., Wilson, S., & Bloom, S. R. (2003). Effect of direct injection of melanin-concentrating hormone into the paraventricular nucleus: Further evidence for a stimulatory role in the adrenal axis via SLC-1. *J Neuroendocrinol.* **15**, 268-272.

Kim, K. M., Nakajima, Y., & Nakajima, S. (1995). G-Protein-Coupled Inward Rectifier Modulated by Dopamine Agonists in Cultured Substantia-Nigra Neurons. *Neurosci.* **69**, 1145-1158.

Leibowitz, S. F. & Brown, L. L. (1980). Histochemical and Pharmacological Analysis of Catecholaminergic Projections to the Perifornical Hypothalamus in Relation to Feeding Inhibition. *Brain Res.* **201**, 315-345.

Lembo, P. M. C., Grazzini, E., Cao, J., Hubatsch, D. A., Pelletier, M., Hoffert, C., St Onge, S., Pou, C., Labrecque, J., Groblewski, T., O'Donnell, D., Payza, K., Ahmad, S., & Walker, P. (1999). The receptor for the orexigenic peptide melanin-concentrating hormone is a G-protein-coupled receptor. *Nature Cell Biol.* **1**, 267-271.

Ludwig, D. S., Tritos, N. A., Mastaitis, J. W., Kulkarni, R., Kokkotou, E., Elmquist, J., Lowell, B., Flier, J. S., & Maratos-Flier, E. (2001). Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. *J Clin Invest.* **107**, 379-386.



Marsh, D. J., Weingarth, D. T., Novi, D. E., Chen, H. Y., Trumbauer, M. E., Chen, A. S., Guan, X. M., Jiang, M. M., Feng, Y., Camacho, R. E., Shen, Z., Frazier, E. G., Yu, H., Metzger, J. M., Kuca, S. J., Shearman, L. P., Gopal-Truter, S., MacNeil, D. J., Strack, A. M., MacIntyre, D. E., Van der Ploeg, L. H. T., & Qian, S. (2002). Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. *PNAS*. **99**, 3240-3245.

Michelotti, G.A., Price, D.T., Schwinn, D.A. (2000). Alpha1-Adrenergic receptor regulation: basic science and clinical implications: *Pharmacol Ther*. **88**. 281-309.

Missale, C., Nash, S. R., Robinson, S. W., Jaber, M., & Caron, M. G. (1998). Dopamine receptors: From structure to function. *Physiol Rev*. **78**, 189-225.

Modirrousta, M., Mainville, L., & Jones, B. E. (2005). Orexin and MCH neurons express c-Fos differently after sleep deprivation vs. recovery and bear different adrenergic receptors. *Eur J Neurosci*. **21**, 2807-2816.

Morilak, D. A., Barrera, G., Echevarria, D. J., Garcia, A. S., Hernandez, A., Ma, S., & Petre, C. O. (2005). Role of brain norepinephrine in the behavioral response to stress. *Prog Neuro-Psychoph*. **29**, 1214-1224.

Otis, T., De Koninck, Y., & Mody, J. (1993). Characterization of synaptically elicited GABA<sub>B</sub> responses using patch-clamp recordings in rat hippocampal slices. *J Physiol*. **463**. 391-407.

Parada, M. A., Hernandez, L., & Hoebel, B. G. (1988). Sulpiride Injections in the Lateral Hypothalamus Induce Feeding and Drinking in Rats. *Pharmacol Biochem Behav*. **30**, 917-923.

Peyron, C., Tighe, D. K., van den Pol, A. N., de Lecea, L., Heller, H. C., Sutcliffe, J. G., & Kilduff, T. S. (1998). Neurons containing hypocretin (orexin) project to multiple neuronal systems. *J Neurosci*. **18**, 9996-10015.

Qu, D. Q., Ludwig, D. S., Gammeltoft, S., Piper, M., Pelleymounter, M. A., Cullen, M. J., Mathes, W. F., Przypek, J., Kanarek, R., & Maratos-Flier, E. (1996). A role for melanin-concentrating hormone in the central regulation of feeding behaviour. *Nature* **380**, 243-247.



Racotta, R., Sotomora, L. M., Palacios, E., & Quevedo, L. (1995). Norepinephrine Inhibition of Water and Food-Intake - Comparison with Vasopressin Effects. *Physiol Behav.* **57**, 141-145.

Rodriguez, M., Beauverger, P., Naime, I., Rique, H., Ouvry, C., Souchaud, S., Dromaint, S., Nagel, N., Suply, T., Audinot, V., Boutin, J. A., & Galizzi, J. P. (2001). Cloning and molecular characterization of the novel human melanin-concentrating hormone receptor MCH2. *Mol Pharmacol.* **60**, 632-639.

Rossi, M., Choi, S. J., Oshea, D., Miyoshi, T., Ghatei, M. A., & Bloom, S. R. (1997). Melanin-Concentrating hormone acutely stimulates feeding, but chronic administration has no effect on body weight. *Endocrinology* **138**, 351-355.

Sailer, A., Sano, H., Zeng, Z., McDonald, T., Pan, J., Pong, S., Feighner, S., Tan, C., Fukami, T., Iwaasa, H., Hreniuk, D., Morin, N., Sadowski, S., Ito, M., Bansal, A., Ky, B., Figueroa, D., Jiang, Q., Austin, C., MacNeil, D., Ishihara, A., Ihara, M., Kanatani, A., Van der Ploeg, L., Howard, A., Liu, Q. (2001). Identification and characterization of a second melanin-concentrating hormone receptor, MCH-2R. *PNAS.* **98**, 7564-7569.

Saito, Y., Cheng, M., Leslie, F. M., & Civelli, O. (2001). Expression of the melanin-concentrating hormone (MCH) receptor mRNA in the rat brain. *J Comp Neurol.* **435**, 26-40.

Saito, Y., Nothacker, H. P., & Civelli, O. (2000). Melanin-concentrating hormone receptor: An orphan receptor fits the key. *Trends Endocri Met.* **11**, 299-303.

Saito, Y., Nothacker, H. P., Wang, Z. W., Lin, S. H. S., Leslie, F., & Civelli, O. (1999). Molecular characterization of the melanin-concentrating-hormone receptor. *Nature* **400**, 265-269.

Sakurai T. (2006). Roles of orexins and orexin receptors in central regulation of feeding behavior and energy homeostasis. *CNS Neurol Disord Drug Targets.* **5**, 313-25

Sanchez, M., Baker, B. I., & Celis, M. (1997). Melanin-concentrating hormone (MCH) antagonizes the effects of alpha-MSH and neuropeptide E-I on grooming and locomotor activities in the rat. *Peptides* **18**, 393-396.

Saper, C. B., Chou, T. C., & Elmquist, J. K. (2002). The need to feed: Homeostatic and hedonic control of eating. *Neuron* **36**, 199-211.

Saugstad, J., Segerson, T., & Westbrook G. (1996). Metabotropic Glutamate Receptors Activate G-Protein-Coupled Inwardly Rectifying Potassium Channels in *Xenopus* Oocytes. *J Neurosci.* **16**, 5979-5985.

Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000). Central nervous system control of food intake. *Nature* **404**, 661-671.

Sederholm, F., Johnson, A. E., Brodin, U., & Sodersten, P. (2002). Dopamine D-2 receptors and ingestive behavior: brainstem mediates inhibition of intraoral intake and accumbens mediates aversive taste behavior in male rats. *Psychopharmacology* **160**, 161-169.

Shimada, M., Tritos, N. A., Lowell, B. B., Flier, L. S., & Maratos-Flier, E. (1998). Mice lacking melanin-concentrating hormone are hypophagic and lean. *Nature* **396**, 670-674.

Shimomura, Y., Mori, M., Sugo, T., Ishibashi, Y., Abe, M., Kurokawa, T., Onda, H., Nishimura, O., Sumino, Y., & Fujino, M. (1999). Isolation and identification of melanin-concentrating hormone as the endogenous ligand of the SLC-1 receptor. *Biochem Bioph Res Co.* **261**, 622-626.

Shiraishi, T. (1991). Noradrenergic neurons modulate lateral hypothalamic chemical and electrical stimulation-induced feeding by sated rats. *Brain Res Bull.* **27**, 347-51.

Tan CP, Sano H, Iwaasa H, Pan J, Sailer AW, Hreniuk DL, Feighner SD, Palyha OC, Pong SS, Figueroa DJ, Austin CP, Jiang MM, Yu H, Ito J, Ito M, Guan XM, MacNeil DJ, Kanatani A, Van der Ploeg LH, Howard AD (2002) Melanin-concentrating hormone receptor subtypes 1 and 2: species-specific gene expression. *Genomics* **79**,785-792.

Trask, R., Alberto, C., Quinlan, M., and Hirasawa, M. (2006). Dopamine inhibits melanin-concentrating hormone expressing neurons through pre-and postsynaptic mechanisms. Soc. Neurosci. Abstr. Atlanta, GA.



van den Pol, A. N., Acuna-Goycolea, C., Clark, K. R., & Ghosh, P. K. (2004). Physiological properties of hypothalamic MCH neurons identified with selective expression of reporter gene after recombinant virus infection. *Neuron* **42**, 635-652.

Vaughan, J. M., Fischer, W. H., Hoeger, C., Rivier, J., & Vale, W. (1989). Characterization of Melanin-Concentrating Hormone from Rat Hypothalamus. *Endocrinology* **125**, 1660-1665.

Velimirovic, B., Koyano, K., Nakajima, S., & Nakajima Y. (1995). Opposing mechanisms of regulation of a G-protein-coupled inward rectifier K<sup>+</sup> channel in rat brain neurons. *Proc Natl Acad Sci USA*. **92**, 1590-1594.

Wang, G. S., Chang, N. C., Wu, S. C., & Chang, A. C. (2002). Regulated expression of alpha 2B adrenoceptor during development. *Dev Dynam*. **225**, 142-152.

Wellman, P., Davies, B., Morien, A., & McMahon, L. (1993). Modulation of feeding by hypothalamic paraventricular nucleus alpha1 and alpha2 adrenergic receptors. *Life Sci*. **53**, 669-679.

Westerfield, D. B., Pang, P. K. T., & Burns, J. M. (1980). Some Characteristics of Melanophore-Concentrating Hormone (Mch) from Teleost Pituitary-Glands. *Gen Comp Endocr*. **42**, 494-499.

WinzerSerhan, U. H., Raymon, H. K., Broide, R. S., Chen, Y., & Leslie, F. M. (1997). Expression of alpha(2) adrenoceptors during rat brain development .1. alpha(2A) messenger RNA expression. *Neurosci*. **76**, 241-260.


Wollmann, G., Acuna-Goycolea, C., & van den Pol, A. N. (2005). Direct excitation of hypocretin/orexin cells by extracellular ATP at P2X receptors. *J Neurophysiol*. **94**, 2195-2206.

Yang, Z. J., Meguid, M. M., Chai, J. K., Chen, C., & Oler, A. (1997). Bilateral hypothalamic dopamine infusion in male Zucker rat suppresses feeding due to reduced meal size. *Pharmacol Biochem Behav*. **58**, 631-635.


Yoshida, K., McCormack, S., Espana, R. A., Crocker, A., & Scammell, T. E. (2006). Afferents to the orexin neurons of the rat brain. *J Comp Neurol*. **494**, 845-861.



Zhang, Y. Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994). Positional Cloning of the Mouse Obese Gene and Its Human Homolog. *Nature* **372**, 425-432.




**Figure 1.** Identification of MCH and orexin neurons. **A1**, Electrophysiological characteristics of an MCH neuron. In a typical MCH neuron, hyperpolarization does not induce an H current and there is no rebound depolarization at the current offset. There are no spontaneous action potential firing at rest and depolarization induces a strong spike rate adaptation(*i*). **A2**, Electrophysiological characteristics of an Orexin neuron. In a typical orexin neuron, hyperpolarization induces an H current(*ii*) and there is a rebound depolarization at the current offset(*iii*). There are spontaneous action potential firing at rest and depolarization does not induce spike rate adaptation. **B1**, Immunohistological identification of a recorded MCH neuron. Left, an example of a cell filled with biocytin during recording. Middle, MCH immunoreactivity is shown in green. Right, overlay showing the biocytin labeled cell is MCH-immunopositive. **B2**, Immunohistological identification of a recorded orexin neuron. Left, an example of a cell filled with biocytin during recording. Middle, orexin A neuropeptide immunoreactivity is shown in red. Right, overlay showing the biocytin labeled cell is orexin A-immunopositive.




**Figure 2.** DA hyperpolarizes and diminishes firing of MCH neurons. **A**, Top, Typical recording showing the effect of 100μM DA. The bar above the trace indicates application of DA. Vertical lines are responses to current injections (-200~200pA). Bottom, Representative recording during 200pA injections in expanded time scale taken at the time points indicated by each arrow. Note the reduction in action potential firing and the increase in action potential latency during DA application. **B1**, Effect of 10 and 100μM DA on action potential firing during a 200pA, 300ms current step. **B2**, Effect of 10 and 100μM DA on the latency to the first action potential during a 200pA, 300ms current step. **B3**, Effect of 10 and 100μM DA on input resistance during a 200pA, 300ms current step. Error bars indicate SE. Numbers above and within bars represents the number of samples used.






**Figure 3.** DA induces a concentration dependent outward current in MCH neurons. **A**, Typical recording showing the effect of 100 $\mu$ M DA. **B**, Summary of DA effect at different concentrations. \* $p < 0.05$ . Error bars indicate SE. Numbers above and within bars represents the number of samples used.




**Figure 4.** DA-induced outward current due to the activation of GIRK channels in MCH neurons. **A1**, Representative traces showing the effect of DA application on I-V relationship during a 600ms voltage ramp. **A2**, Representative trace showing the total DA induced current with a reversal potential of -91pA (arrow). **B1**, Typical recording showing the effect of 100μM DA in the presence of Tertiapin-Q (300nM). **B2**, Summary of the effect of 100μM DA in the presence of Tertiapin-Q (300nM). \* $p < 0.05$ . Error bars indicate SE. Numbers above and within bars represents the number of samples used.




**Figure 5.** DA-induced outward current is initiated through the activation of  $\alpha_2$ -adrenoceptors and not DA receptors in MCH neurons. **A**, Typical recording showing the effect of SKF81297 (10 $\mu$ M) and Quinpirole (10 $\mu$ M). **B**, Typical recording showing the effect of 100 $\mu$ M DA in the presence of SCH23390 (10 $\mu$ M) and Sulpiride (10 $\mu$ M). **C**, Typical recording showing the effect of 100 $\mu$ M DA in the presence of Yohimbine (5 $\mu$ M). **D**, Summary of the effect of DA, SKF81297 plus Quinpirole, DA in the presence of SCH23390 and Sulpiride, DA in the presence of Yohimbine on MCH neurons. Concentration of DA used was 10-100 $\mu$ M. \* $p < 0.05$ . Error bars indicate SE. Numbers above and within bars represents the number of samples used..






**Figure 6.** DA-induced outward current is due to the activation of  $\alpha_{2A}$ -adrenoceptors in MCH neurons. **A**, Typical recording showing the effect of 100  $\mu$ M DA in the presence of BRL44408 (3  $\mu$ M). **B**, Typical recording showing the effect of 100  $\mu$ M DA in the presence of Imiloxan (3  $\mu$ M). **C**, Summary of the effect on DA, DA in the presence of BRL 44408, DA in the presence of Imiloxan on MCH neurons. The concentration of DA used was 10-100  $\mu$ M. \* $p < 0.05$ . Error bars indicate SE. Numbers above and within bars represents the number of samples used.



**Figure 7.** DA and NE-induced outward currents are similar in MCH neurons. **A**, Typical recording showing the effect of 100  $\mu$ M NE. **B**, Concentration dependence of DA and NE-induced outward currents. Number of samples used: 0.1  $\mu$ M (DA=3 NE=4), 1  $\mu$ M (DA=4 NE=4), 3  $\mu$ M (DA=5 NE=4), 10  $\mu$ M (DA=5, NE=3), 100  $\mu$ M (DA=13, NE=5). **C**, Preliminary recording showing the effect of 100  $\mu$ M NE in the presence of 100  $\mu$ M DA. Error bars indicate SE.



**Figure 8.** DA has no consistent effect on mIPSC frequency or amplitude. **A1**, Summary of the effect of various concentrations of DA on mIPSC frequency (each filled circle represents a single cell). **A2, A3, A4**, Representative time effect plots of 100  $\mu$ M DA effect on mIPSC frequency. **B**, Summary of the effect of various concentrations of DA on mIPSC Amplitude (each filled circle represents a single cell).











